Submitted by Organon
Organon announces company’s formal commitment to FP2030 at International Conference on Family Planning in Pattaya City, Thailand
Company aims to accelerate progress against FP2030’s goal of ensuring global access to contraceptive options
November 14, 2022 /CSRwire/ - Organon (NYSE: OGN), a global women’s healthcare company, today announced its formal commitment to FP2030 to help prevent 120 million unintended pregnancies by 2030. Recognizing the urgency of the crisis, Organon is taking action to scale access to contraceptive options for more than 100 million women in low- and middle-income countries (LMICs), in addition to strategic partnerships focused on education, training, advocacy and youth engagement. This FP2030 commitment aligns with Organon’s Her Promise platform which launched earlier this year to address gender-related disparities in health to help women and girls achieve their promise.
The United Nations Population Fund (UNFPA) has deemed the high rates of unintended pregnancy a global public health crisis. Annually, nearly 50% of pregnancies around the world are estimated to be unintended, and over 160 million women and girls have an unmet need for contraception. As the only global company of its size dedicated to women’s health, Organon is well positioned to help address this crisis. Organon’s commitment to FP2030 is positioned to help to reduce these high rates of unintended pregnancies, and focuses efforts on expanding access to contraception for women and girls in 73 low- and middle-income countries, where there is significant need.
“When women and girls have access to contraception resources and options, they can unlock their fullest potential – and that of their families, societies and economies,” said Kevin Ali, Organon’s Chief Executive Officer. “Organon is pleased to stand with FP2030 and the family planning community with our commitment to help prevent 120 million unintended pregnancies around the world where there is the greatest need.”
Organon’s largest program, the Her Promise Access Initiative, is executed with the support of a network of collaborators worldwide, including UNFPA and the Bill & Melinda Gates Foundation, and aims to expand access to information, training and cost-effective contraceptive options so that women and girls can make informed reproductive decisions – including about when and if they start a family. Working through global partnerships, Organon is directly addressing these needs and helping to deliver on its FP2030 commitment and help millions of women and girls take control of their reproductive health.
FP2030 is a global platform and measurement framework dedicated to advancing progress towards equitable and accessible family planning by 2030, and governments and stakeholders have the opportunity to join by making a formal commitment in line with the organization’s principles.
“We’re thrilled to welcome Organon as a new commitment maker through FP2030,” said Dr. Samukeliso Dube, Executive Director at FP2030. “Organon’s commitment to addressing the needs of women and girls further emphasizes the importance and profound impact of cross-sectoral collaboration, and the value that our private sector partners bring to drive collective progress.”
Organon is a global healthcare company with a focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women’s health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in innovation and future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.
For more information, visit www.organon.com and connect with us on LinkedIn and Instagram.
Organon makes various statements in this press release, including, but not limited to, statements about management’s expectations about Organon’s commitment to FP2030 and related expectations and targets. These “forward-looking statements” may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon’s filings with the Securities and Exchange Commission ("SEC"), including the company’s Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent SEC filings, available at the SEC’s Internet site (www.sec.gov).
Karissa Peer, Media Relations
More from Organon